#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malignant oligodendroglioma Primary biliary cholangitis Bronchopulmonary dysplasia Ventricular tachycardia Autoimmune disorder Penile cancer HER2 mutant non-small cell lung cancer Alveolar rhabdomyosarcoma Dilated cardiomyopathy Osteogenesis imperfecta Usher's syndrome Urea cycle disorder Synovial sarcoma Pleomorphic leiomyosarcoma Immune-mediated myasthenia gravis More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma stage III – Life with Disease Leiomyosarcoma – Diagnostics Congenital hypotransferrinaemia – Diagnostics Biotinidase deficiency – Basic Information Angiosarcoma metastatic – Basic Information Proteus syndrome – Trials in Disease Haemophilia B with anti factor IX Combined immunodeficiency – Treatment MELAS syndrome Angelman’s syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Caspofungin Esomeprazole Dacarbazine Ep262 PEGVISOMANT Ticagrelor Lumateperone Diphenhydramine Hydrochloride Daunorubicin Azelastine Magnesium Hydroxide Gemtuzumab Ozogamicin Human Coagulation Factor Ii Eptacog Beta (Activated) Lanreotide Gsk3858279 Capecitabine Aceclofenac ABY-271 Buserelin Acetate More therapies…

    Learn about Your Condition

    Mitral valve disease Polymyalgia rheumatica Implantation complication Rectal adenocarcinoma Acoustic neuroma Immune-mediated myositis Dysmenorrhoea Meniscus injury Cervix carcinoma stage II Facial paresis Cortical dysplasia Craniocerebral injury Nodular melanoma Hepatitis B Cerebrovascular accident More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study on the Safety and Effectiveness of Hydroxypropylbetadex and Miglustat for Patients with Niemann-Pick Disease Type C1

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Niemann-Pick disease
    Investigated Drugs:
    • Hydroxypropylbetadex
    • Miglustat
    Germany Italy Poland Spain

  • Study on the Effectiveness and Safety of Bimekizumab and Risankizumab in Adults with Active Psoriatic Arthritis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Bimekizumab
    • Risankizumab
    Bulgaria Czechia Germany Hungary Poland Spain

  • Study on Evolocumab for Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Evolocumab
    France Germany Italy Poland Spain

  • Study on EYE103 and Ranibizumab for Patients with Diabetic Macular Edema

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Macular oedema
    • Diabetic retinal oedema
    Investigated Drugs:
    • Eye103
    • Fluorescein Sodium
    • Ranibizumab
    Austria Croatia Czechia France Germany Hungary +6

  • Study on the Effects of Povetacicept for Adults with IgA Nephropathy

    Not recruiting

    3 1
    Investigated Diseases:
    • Nephropathy
    Investigated Drugs:
    • Povetacicept
    Austria Belgium Croatia Czechia Denmark Estonia +13

  • Study on Balstilimab for Patients with Advanced Non-Melanoma Skin Cancers

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Skin cancer
    • Basal cell carcinoma
    Investigated Drugs:
    • Balstilimab
    Poland
Previous Page
1 … 1,676 1,677 1,678 1,679 1,680 … 1,695
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!